Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
β Scribed by Pullarkat, S T; Stoehlmacher, J; Ghaderi, V; Xiong, Y-P; Ingles, S A; Sherrod, A; Warren, R; Tsao-Wei, D; Groshen, S; Lenz, H-J
- Book ID
- 111937174
- Publisher
- Nature Publishing Group
- Year
- 2001
- Tongue
- English
- Weight
- 116 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1470-269X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Thymidylate synthase (TS) is the primary target of 5βfluorouracil (5βFU). A VNTR polymorphism in the TS promoter region is associated with the efficacy of 5βFUβbased chemotherapy in colorectal cancer. A common G>C SNP at the 12th nucleotide of the second repeat in the TS\*3 alleles has
## Abstract While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5βFluorouracil (5βFU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPTβ11)